Publications by authors named "Tommaso Sani"
Article Synopsis
- Immune-checkpoint inhibitors (ICIs) can cause immune-related adverse events (irAEs), with immune-mediated pneumonitis (im-PN) being a rare but serious complication that requires prompt diagnosis and management to prevent severe outcomes and allow for continued cancer treatment.
- A study collected data from 1004 cancer patients treated with ICIs, finding that 24 (2%) developed im-PN, with varying degrees of severity; most patients responded well to steroid treatment, leading to recovery in 21 individuals within an average of 14 weeks.
- Three main radiologic patterns of im-PN were identified (organizational pneumonia-like, pulmonary eosinophilia, and hypersensitivity pneumonitis), and bronchoalve
Harnessing the immune system with immune-checkpoint(s) blockade (ICB) has dramatically changed the treatment landscape of advanced melanoma patients in the last decade. Indeed, durable clinical responses and long-term survival can be achieved with anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and anti-Programmed cell Death-1 (PD-1) monoclonal antibodies (mAb) either alone or in combination. Despite these unprecedented results, due to intrinsic or acquired resistance to ICB-based immunotherapy, about half of metastatic melanoma (MM) patients neither respond to therapy nor experience durable clinical benefit or long-term survival.
View Article and Find Full Text PDFHealthcare workers (HCWs) are reluctant to participate in the influenza vaccination program, despite their high risk to contract and diffuse influenza due to professional exposure. The onset of the COVID-19 pandemic could raise HCW flu vaccination adherence. The aim of this study was to assess HCW attitudes toward influenza vaccination in the COVID-19 era.
View Article and Find Full Text PDF